Loading...
Publication: Current advances in the clinical development of anti-tubercular agents
Tetali, S.R. Kunapaeddi, E. Mailavaram, R.P. Singh, V. Borah, P. Deb, P.K. Venugopala, K.N. Hourani, W. Tekade, R.K.
Tetali, S.R.
Kunapaeddi, E.
Mailavaram, R.P.
Singh, V.
Borah, P.
Deb, P.K.
Venugopala, K.N.
Hourani, W.
Tekade, R.K.
Citations
Altmetric:
Abstract
Tuberculosis (TB) is a communicable airborne infectious disease caused by the Mycobacterium tuberculosis (MTB) that primarily affects the lungs, and can disseminate to other parts of the body. MTB is one of the most dangerous pathogens, killing about 1.4 million people annually worldwide. Although the standard treatment of TB is comprised of four anti-TB drugs, the emergence of multidrug-resistant (MDR) and extensive drug-resistant (XDR) strains in the recent past and associated side effects have affected the tailor-made regimens. Notably, existing therapies approved by the World Health Organisation (WHO) can only treat less than 50% of drug-resistant TB.
Therefore, an expeditious pace in the TB research is highly needed in search of effective, affordable, least toxic novel drugs with shorter regimens to reach the goals viz. 2020 milestones End TB strategy set by the WHO. Currently, twenty-three drug-like molecules are under investigation in different stages of clinical trials. These newer agents are expected to be effective against the resistant strains. This article summarizes the properties, merits, demerits, and the probability of their success as novel potential therapeutic agents.
Description
Date
2020-12
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Collections
Research Projects
Organizational Units
Journal Issue
Keywords
Azaindole,Benzimidazoles,Clinical trials,Diarylquinoline,Dihydrocarbostyril,Drug resistance,Ethylenediamine,Fluoroquinolone,Imidazopyridine,Mycobacterium tuberculosis,Nitrothiazoles,Oxaboroles,Oxazolidinones,Rifamycin,Riminophenazine,Tuberculosis,SDG-03 Good health and well-obeing
Citation
Tetali SR, Kunapaeddi E, Mailavaram RP, Singh V, Borah P, Deb PK, Venugopala KN, Hourani W, Tekade RK. Current advances in the clinical development of anti-tubercular agents. Tuberculosis (Edinb). 2020 Dec;125:101989. doi: 10.1016/j.tube.2020.101989.